179 Early real-world experience of ocrelizumab in MS. Issue 12 (14th November 2019)

• Record Type: Journal Article
• Authors: Harding, Katharine; Ingram, Gillian; Horton, Emma; Owen, Helen; Joseph, Fady; Pearson, Owen
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 90:Issue 12(2019)
• Page Start: e47
• Page End: e47
• Publication Date: 2019-11-14
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2019-ABN-2.159
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Background: Ocrelizumab was recently licensed for use in relapsing-remitting multiple sclerosis (MS). We present our clinical experience of ocrelizumab treatment for MS in two specialist centres in south Wales. Methods: All patients with MS treated with ocrelizumab in Newport and Swansea between 01/08/2018 and 31/12/2018 were included. Sex ratio, age at MS onset and baseline EDSS score were calculated. Data was collated on indication for treatment and adverse effects, and data on previous DMT sequencing will be discussed. Results: Eighty-one patients (82% female) were treated in total. Mean age at onset was 32.4 years, and mean age at ocrelizumab treatment was 42.8 years. Baseline EDSS was <4.0 in 45 (55%), 4.0–6.0 in 24 (30%), and 6.0–6.5 in 12 (15%). The commonest indication was first-line treatment for active disease (n=26, 32%), followed by side effects from other disease-modifying treatment (n=20, 25%), and high JCV titre on natalizumab (n=15, 19%). Sixty-two patients (77%) had no adverse effects. Eleven patients (14%) had infections. Three patients (4%) had infusion reactions. One patient had an allergic reaction to ocrelizumab and discontinued treatment. There were no cases of PML. Discussion: Ocrelizumab has been safe and well-tolerated in our cohort. Our study illustrates the value of real-world clinical data in MS.